Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX treatment (8 cycles of XELOX).

Trial Details

NCT ID
NCT04787354
Phase
PHASE3
Sponsor
Hallym University Medical Center
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Oxaliplatin
  • Capecitabine
Locations (sample)
  • Gyeonggi-do, South Korea|37.58944,126.76917

Key Eligibility Criteria

  • Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma patients who underwent curative surgery (D1 beta or D…
  • Pathologically confirmed stage II, III patients (AJCC 8th edition)
  • Age 19 years and older
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →